Volume : 12, Issue : 06, June – 2025
Title:
UNDERSTANDING BA/BE STUDIES FOR ORALLY ADMINISTERED MODIFIED RELEASE DRUG PRODUCTS IN US AND EU MARKETS: A REGULATORY REVIEW
Authors :
P Sai Krishna*, G.Ramakrishna, M.V.Nagabhushanam
Abstract :
Bioavailability (BA) and bioequivalence (BE) studies are critical components in the development and approval of orally administered modified release (MR) drug products. These studies ensure therapeutic consistency between test and reference products and maintain patient safety and efficacy. However, regulatory frameworks differ slightly between the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This review provides a comprehensive understanding of the BA/BE study requirements for modified release formulations in both regions, highlighting similarities, key differences, challenges, and recent advancements.
Keywords: Bioavailability (BA), Bioequivalence (BE), Modified Release (MR) Drug products, United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Cite This Article:
Please cite this article in press P Sai Krishna et al., Understanding Ba/Be Studies For Orally Administered Modified Release Drug Products In Us And Eu Markets: A Regulatory Review., Indo Am. J. P. Sci, 2025; 12(07).
Number of Downloads : 10
References:
1. FDA Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations.
2. EMA Guideline on the Investigation of Bioequivalence, 2010.
3. FDA Product-Specific Guidances for Modified Release Dosage Forms.
4. European Medicines Agency, Questions & Answers on Bioequivalence.
5. Dressman, J.B. et al. (2019). “Modified-Release Drug Products: Regulatory Challenges and Scientific Approaches.” AAPS Journal.
6. Yu, L.X. et al. (2016). “Advances in Bioavailability and Bioequivalence Evaluation.” Clinical Pharmacokinetics.
7. EMA Q&A: Quality of medicines – modified release formulations.
8. Brahmaiah Bonthagarala, Regulatory process and ethics for clinical trials in India (CDSCO)- A Review, The Pharma Innovation Journal, ISSN (E): 2277- 7695 , ISSN (P): 2349-8242,2017; 6(4): 165-169.
9. Brahmaiah Bonthagarala, Evaluation of Pharmaceutical Regulatory Systems & Present Scenario of Indian Pharmaceutical Industry, World Journal of Pharmaceutical Research, ISSN 2277–7105, 2017, Volume 6, Issue 5, 368-379.
10. Brahmaiah Bonthagarala, Regulatory Requirements of ‘Similar Biologics’ for Marketing Authorization in India, International Journal of Drug Regulatory Affairs, ISSN: 2321 – 6794; 2017, 5(1), 20-24.
11. Brahmaiah Bonthagarala, Guidelines for bioavailability and bioequivalence studies: A Review, The Pharma Innovation Journal 2018; 7(7): 661-666, ISSN (E): 2277- 7695.
12. Brahmaiah Bonthagarala, A Review on global harmonization task force (GHTF) – principles of in vitro diagnostic (IVD) medical devices classification, The Pharma Innovation Journal 2018; 7(7): 667-672, ISSN (E): 2277- 7695.
13. FDA Guidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations.